Merus N.V.

NasdaqGM MRUS

Merus N.V. Current Liabilities for the year ending December 31, 2023: USD 69.09 M

Merus N.V. Current Liabilities is USD 69.09 M for the year ending December 31, 2023, a -12.46% change year over year. Current liabilities are obligations that are expected to be settled within one year, including accounts payable, short-term debt, and other current liabilities.
  • Merus N.V. Current Liabilities for the year ending December 31, 2022 was USD 78.93 M, a 9.77% change year over year.
  • Merus N.V. Current Liabilities for the year ending December 31, 2021 was USD 71.90 M, a 53.81% change year over year.
  • Merus N.V. Current Liabilities for the year ending December 31, 2020 was USD 46.75 M, a 27.07% change year over year.
  • Merus N.V. Current Liabilities for the year ending December 31, 2019 was USD 36.79 M, a -3.02% change year over year.
Key data
Date Current Liabilities Total Non-Current Liabilities Shareholders' Equity Long-Term Debt
Market news
Loading...
NasdaqGM: MRUS

Merus N.V.

CEO Dr. Sven Ante Lundberg M.D.
IPO Date May 19, 2016
Location Netherlands
Headquarters Yalelaan 62
Employees 172
Sector Health Care
Industries
Description

Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Similar companies

SNDX

Syndax Pharmaceuticals, Inc.

USD 12.60

-1.56%

LRMR

Larimar Therapeutics, Inc.

USD 3.29

-5.46%

ADAG

Adagene Inc.

USD 1.80

1.12%

KURA

Kura Oncology, Inc.

USD 7.26

0.28%

MLYS

Mineralys Therapeutics, Inc.

USD 9.12

-2.56%

PTGX

Protagonist Therapeutics, Inc.

USD 36.67

-1.26%

CRNX

Crinetics Pharmaceuticals, Inc.

USD 35.62

-8.62%

PCVX

Vaxcyte, Inc.

USD 78.14

-3.73%

ACRV

Acrivon Therapeutics, Inc. Common Stock

USD 5.56

0.91%

ANEB

Anebulo Pharmaceuticals, Inc.

USD 1.60

5.96%

REPL

Replimune Group, Inc.

USD 10.49

-3.67%

ANAB

AnaptysBio, Inc.

USD 14.91

1.98%

INBX

Inhibrx Biosciences, Inc.

USD 12.74

-6.60%

STRO

Sutro Biopharma, Inc.

USD 1.72

-3.91%

StockViz Staff

January 15, 2025

Any question? Send us an email